Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

• Main Authors: Bin Lin (Author), Yangmin Hu (Author), Ping Xu (Author), Tao Xu (Author), Chunyan Chen (Author), Le He (Author), Mi Zhou (Author), Zhangzhang Chen (Author), Chunhong Zhang (Author), Xuben Yu (Author), Luo Fang (Author), Junfeng Zhu (Author), Yanlan Ji (Author), Qun Lin (Author), Hengbin Cao (Author), Youqin Dai (Author), Xiaoyan Lu (Author), Changcheng Shi (Author), Li Li (Author), Changjiang Wang (Author), Xumei Li (Author), Qiongyan Fang (Author), Jing Miao (Author), Zhengyi Zhu (Author), Guangyong Lin (Author), Haichao Zhan (Author), Shiwen Lv (Author), Yalan Zhu (Author), Xinjun Cai (Author), Yin Ying (Author), Meng Chen (Author), Qiong Xu (Author), Yiwen Zhang (Author), Yubin Xu (Author), Pea Federico (Author), Saiping Jiang (Author), Haibin Dai (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individual...